We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Presents Future of Diagnostic Technology

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The Vivalytic all-in-one solution for molecular diagnostics (Photo courtesy of Randox)
Image: The Vivalytic all-in-one solution for molecular diagnostics (Photo courtesy of Randox)

Randox Laboratories (Crumlin, UK) is showcasing its extensive range of innovative products that are revolutionizing healthcare at the 2023 EuroMedLab Congress.

At EuroMedLab Rome 2023, Randox is introducing the new Acusera third-party controls designed for comprehensive test menu consolidation in laboratory internal quality control. These third-party controls are "true," meaning they are not biased towards or optimized for any specific reagent, method, or instrument, and hence offer an objective assessment of performance. Notably, several Acusera controls are produced using 100% human materials, mimicking a patient sample's behavior and thus providing an accurate reflection of the test system's performance.

Also on display at the industry event is Randox's Vivalytic, an all in one molecular diagnostic solution. This compact benchtop platform consolidates the complete molecular workflow, including extraction, PCR amplification, and detection. The unique multiplex Biochip Technology from Randox powers the Vivalytic, yielding multiple results from a single patient sample. The biochip detection system based on a chemiluminescent signal, which is the emission of light without heat from a chemical reaction. Each biochip is pre-engineered with spatially distinct testing regions (DTRs), each representing an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest, allowing the high-plex capabilities of the Biochip Technology to eliminate the need for running multiple, time-consuming, and sample-intensive assays.

Randox is holding live demonstrations of ACUSERA 24•7 Interlaboratory Data Management which provides instant access to an unrivalled range of features including QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface, all designed to speed up the review process and provide at-a-glance performance assessment. Randox is also demonstrating RIQAS (Randox International Quality Assessment Scheme which is used by more than 55,000 laboratory participants in 134 countries and accredited to ISO 17043. As a result, Randox has RIQAS users on every continent who are registered for one or more of its 36 flexible EQA programs, utilizing the available data to ensure the quality and reliability of their results.

ACUSERA 24•7 Interlaboratory Data Management, a feature-rich platform offering QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface. All these features are designed to expedite the review process and provide at-a-glance performance assessment. Further, Randox is also demonstrating its RIQAS (Randox International Quality Assessment Scheme), an ISO 17043-accredited scheme employed by over 55,000 lab participants across 134 countries. Thanks to its global footprint, Randox has RIQAS users in every continent who are registered for one or more of its 36 flexible EQA programs, thereby leveraging available data to assure the quality and dependability of their results.

Related Links:
Randox Laboratories 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.